Treatment options that have been tried include zidovudine and the CHOP regimen. Pralatrexate has also been investigated. Recently, it has been reported that the traditional glucocorticoid-based chemotherapy toward ATL are largely mediated by thioredoxin binding protein-2 (TBP-2/TXNIP/VDUP1), suggesting the potential use of a TBP-2 inducer as a novel therapeutic target. In 2021, mogamulizumab was approved for relapsed/refractor treatment of ATL in Japan. At a medical conference in December 2013, researchers reported anywhere from 21-50% of ATL patients have disease expressing CD30. Although not FDA approved, treatment with CD30-targeting brentuximab vedotin in CD 30+ cases may be beneficial and supported by current NCCN guidelines.
wiki page disambiguates of T-cell leukemia
symptom of Biphenotypic acute leukaemia
symptoms of Biphenotypic acute leukaemia
types of Acute lymphoblastic leukemia
symptom of Acute myeloid leukemia
medical cause of Neutropenia
symptom of Chronic lymphocytic leukemia
symptom of Chronic multifocal Langerhans cell histiocytosis